Oncolytics Biotech Inc. Receives Nasdaq Non-Compliance Notice for Minimum Bid Price Requirement
Key Points:
- Oncolytics Biotech Inc. (NASDAQ: ONCY) received a formal notice from the Nasdaq Listing Qualifications Staff on July 20, 2026, regarding non-compliance with the \$1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market.
- The company’s common stock has closed below \$1.00 per share for 30 consecutive business days, triggering the deficiency notice.
- Oncolytics Biotech’s common stock will continue to trade under the ticker “ONCY” on the Nasdaq Capital Market during the compliance period.
- The company has 180 calendar days (until January 19, 2027) to regain compliance by maintaining a closing bid price of at least \$1.00 per share for a minimum of 10 consecutive business days.
- If compliance is not regained, Oncolytics Biotech may be eligible for an additional 180-day period, subject to satisfying other initial listing requirements and notifying Nasdaq of its intent to cure the deficiency.
- Failure to regain compliance within the allotted period could result in the delisting of Oncolytics Biotech’s common stock from the Nasdaq Capital Market.
- The company is actively monitoring its stock price and evaluating available options to regain compliance, but there is no assurance that it will be successful.
Details and Analysis for Investors:
Oncolytics Biotech Inc., a biotechnology company listed on the Nasdaq Capital Market, announced that it has received a notification from Nasdaq’s Listing Qualifications Staff indicating that the company is not in compliance with the minimum bid price requirement, as stipulated in Nasdaq Listing Rule 5550(a)(2). The rule requires companies to maintain a minimum closing bid price of \$1.00 per share in order to remain listed on the exchange.
According to the notice received on July 20, 2026, Oncolytics Biotech’s common stock, which has a par value of \$0.001 per share, traded below the \$1.00 threshold for 30 consecutive business days. As a result, the company was deemed out of compliance, which may raise concerns for shareholders regarding the company’s continued listing and overall market perception.
Importantly, the notice does not immediately affect the company’s listing status. The shares will continue to be traded on Nasdaq under the symbol “ONCY,” provided that Oncolytics complies with all other listing requirements.
The company now has a 180-day “Compliance Period,” ending on January 19, 2027, to resolve the deficiency. During this period, if the closing bid price of ONCY shares is at least \$1.00 for a minimum of 10 consecutive business days (unless Nasdaq staff extends this period at their discretion), the company will be notified in writing that it has regained compliance, and the matter will be considered closed.
If Oncolytics Biotech fails to meet the minimum bid price requirement within the initial 180-day period, it may be eligible for an additional 180-day extension—provided that it satisfies all other initial listing requirements for the Nasdaq Capital Market (excluding the minimum bid price) and notifies Nasdaq of its intent to cure the deficiency. However, if the company cannot regain compliance within the permitted timeframe, or if it fails to meet other listing standards, its shares may be subject to delisting from Nasdaq.
Shareholder Impact and Price Sensitivity:
- This notification is a material event and may be considered price-sensitive information. A potential delisting could have significant negative effects on liquidity, investor confidence, and the company’s ability to attract institutional investment.
- Shareholders should be aware that the company is evaluating options to regain compliance, which may include corporate actions such as a reverse stock split, changes to business strategy, or other measures to boost the share price.
- There is no guarantee that Oncolytics Biotech will be able to regain compliance or remain listed on Nasdaq, which increases risk for both current and prospective investors.
Corporate Response:
The company’s management has stated that it “intends to monitor the closing bid price of the Common Stock and assess its available options to regain compliance with the Minimum Bid Price Requirement and continue listing on the Nasdaq Capital Market.” However, it also cautions that “there can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price Requirement or will otherwise be in compliance with other applicable Nasdaq listing rules.”
Additional Details:
- The notice was signed and filed by Kirk Look, Chief Financial Officer, on July 24, 2026.
- The company’s business address is Suite 325, 4350 Executive Drive, San Diego, CA 92121.
- ONCY is the trading symbol for the common stock registered on The Nasdaq Stock Market LLC.
Disclaimer: This article is intended for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities. Investors should conduct their own due diligence and consult with financial advisors before making investment decisions. The information presented herein is based on the company’s public filing as of July 24, 2026, and may be subject to change.
